Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health.

Thumbnail Image

Files

Stuhec et al 2023.pdf (398.38 KB)

Authors

Stuhec, Matej
Hahn, M
Taskova, I
Bayraktar, I
Fitzgerald, I
Molitschnig, L
Tatarević, A
Lindner, N
Agnoletto, L
da Costa, F Alves

Issue Date

2023-09-27

Type

Journal Article

Language

en

Keywords

Clinical pharmacist interventions , Clinical pharmacy in mental health , European society of clinical pharmacy , Mental illnesses and pharmacy , Pharmaceutical services in mental health , Polypharmacy and clinical pharmacy , Psychotropics and clinical pharmacy

Research Projects

Organizational Units

Journal Issue

Alternative Title

Abstract

A large proportion of the world's disease burden is attributable to mental illnesses. Although effective interventions are available, many patients still have limited access to evidence-based treatments. Aside from access, treatment gaps, including inappropriate medication selection and monitoring, are also routinely recognised. Mental health clinical pharmacists can help address these gaps and enable patients to receive optimised pharmaceutical care, particularly appropriate medication selection and monitoring. The European Society of Clinical Pharmacy (ESCP) Special Interest Group on Mental Health was established to improve standardised service provision in mental health settings across Europe. The Special Interest Group identified significant barriers (predominantly associated with reimbursement and position within the multidisciplinary team) to effective pharmaceutical care amongst those with mental illnesses. This commentary presents recommendations to address these gaps through improved mental health clinical pharmacy service provision.

Description

Citation

Stuhec, M., Hahn, M., Taskova, I. Fitzgerald, I et al. (2023).Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health. Int J Clin Pharm  https://doi.org/10.1007/s11096-023-01643-4

Publisher

License

© 2023. The Author(s).

Journal

International journal of clinical pharmacy

Volume

45

Issue

5

URI

https://repository.stpatricks.ie/handle/internal/233

PubMed ID

37755642

DOI

10.1007/s11096-023-01643-4
10.1016/S2215-0366(21)00395-3
10.1016/j.euroneuro.2011.07.018
10.1016/S0140-6736(21)02143-7
10.1017/S0033291717003336
10.1001/jama.289.23.3095
10.1097/YCO.0000000000000808
10.1016/j.genhosppsych.2009.05.011
10.1177/20451253211011007
10.1007/s00406-017-0798-6
10.3109/13651501.2011.638142
10.1038/s41598-022-15657-x
10.2147/CIA.S192252
10.1016/j.amjopharm.2007.12.002
10.1002/pds.3592
10.1111/jcpt.12811
10.1186/s12913-019-3942-3
10.1016/j.jamda.2017.06.003
10.1007/s00508-013-0342-2
10.1176/appi.ajp.2011.11030347
10.1016/j.euroneuro.2020.03.022
10.1016/j.eurpsy.2017.01.002
10.1001/jamapsychiatry.2018.4320
10.1002/wps.20699
10.1016/j.schres.2017.12.010
10.1192/bjp.bp.111.105833
10.4088/JCP.v64n0107
10.1038/s41537-021-00192-x
10.1001/jamapsychiatry.2013.19
10.24869/psyd.2017.155
10.1016/S0924-9338(99)80713-5
10.3389/fpsyt.2022.885216
10.3389/fpsyt.2020.604201
10.1136/bmjopen-2015-010003
10.3390/pharmacy9030146
10.1592/phco.23.15.1634.31952
10.1007/s11096-013-9900-y
10.9740/mhc.2022.01.015
10.1331/JAPhA.2011.09147
10.1592/phco.23.10.1175.32760
10.1016/j.genhosppsych.2003.08.005
10.1038/s41598-019-53057-w
10.1055/s-0032-1332831
10.1007/s11096-019-00897-1
10.1038/s41598-021-92909-2
10.9740/mhc.2016.09.242
10.9740/mhc.2022.06.193
10.9740/mhc.2020.11.358
10.1007/s11096-021-01321-3
10.1007/s11096-021-01306-2
10.1007/s11096-022-01492-7
10.1007/s11096-022-01422-7
10.1007/s11096-021-01319-x
10.1310/hpj4802-112
10.18549/PharmPract.2020.3.2043

ISSN

2210-7711

EISSN

Collections

Articles